Vaccinia immune globulin: current policies, preparedness, and product safety and efficacy
- PMID: 16564720
- DOI: 10.1016/j.ijid.2005.12.001
Vaccinia immune globulin: current policies, preparedness, and product safety and efficacy
Abstract
In 1980 the World Health Organization declared that smallpox was eradicated from the world, and routine smallpox vaccination was discontinued. Nevertheless, samples of the smallpox virus (variola virus) were retained for research purposes, not least because of fears that terrorist groups or rogue states might also have kept samples in order to develop a bioweapon. Variola virus represents an effective bioweapon because it is associated with high morbidity and mortality and is highly contagious. Since September 11, 2001, countries around the world have begun to develop policies and preparedness programs to deal with a bioterror attack, including stockpiling of smallpox vaccine. Smallpox vaccine itself may be associated with a number of serious adverse events, which can often be managed with vaccinia immune globulin (VIG). VIG may also be needed as prophylaxis in patients for whom pre-exposure smallpox vaccine is contraindicated (such as those with eczema or pregnant women), although it is currently not licensed in these cases. Two intravenous formulations of VIG (VIGIV Cangene and VIGIV Dynport) have been licensed by the FDA for the management of patients with progressive vaccinia, eczema vaccinatum, severe generalized vaccinia, and extensive body surface involvement or periocular implantation following inadvertent inoculation.
Similar articles
-
Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC).MMWR Recomm Rep. 2003 Apr 4;52(RR-7):1-16. MMWR Recomm Rep. 2003. PMID: 12710832
-
Smallpox vaccination and adverse reactions. Guidance for clinicians.MMWR Recomm Rep. 2003 Feb 21;52(RR-4):1-28. MMWR Recomm Rep. 2003. PMID: 12617510
-
Clinical efficacy of intramuscular vaccinia immune globulin: a literature review.Clin Infect Dis. 2004 Sep 15;39(6):819-26. doi: 10.1086/422999. Epub 2004 Aug 23. Clin Infect Dis. 2004. PMID: 15472814 Review.
-
Safety and pharmacokinetic evaluation of intravenous vaccinia immune globulin in healthy volunteers.Clin Infect Dis. 2004 Sep 15;39(6):759-66. doi: 10.1086/422998. Epub 2004 Aug 23. Clin Infect Dis. 2004. PMID: 15472804
-
Smallpox vaccination reactions, prophylaxis, and therapy of complications.Pediatrics. 1975 Mar;55(3):342-7. Pediatrics. 1975. PMID: 238178 Review.
Cited by
-
Anti-Vaccinia Immunoglobulin and Post-exposure Prophylaxis with Vaccinia-based Vaccine for Management of the Monkeypox Outbreak.Actas Dermosifiliogr. 2023 Jan;114(1):92-93. doi: 10.1016/j.ad.2022.08.017. Epub 2022 Sep 5. Actas Dermosifiliogr. 2023. PMID: 36067828 Free PMC article. English, Spanish. No abstract available.
-
A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma.Mol Ther. 2011 Oct;19(10):1913-22. doi: 10.1038/mt.2011.132. Epub 2011 Jul 19. Mol Ther. 2011. PMID: 21772252 Free PMC article. Clinical Trial.
-
Mpox and HIV: a Narrative Review.Curr HIV/AIDS Rep. 2023 Aug;20(4):261-269. doi: 10.1007/s11904-023-00661-1. Epub 2023 May 13. Curr HIV/AIDS Rep. 2023. PMID: 37178205 Free PMC article. Review.
-
Recent Advances in Research and Management of Human Monkeypox Virus: An Emerging Global Health Threat.Viruses. 2023 Apr 10;15(4):937. doi: 10.3390/v15040937. Viruses. 2023. PMID: 37112916 Free PMC article. Review.
-
Functional epitopes and neutralizing antibodies of vaccinia virus.Front Microbiol. 2023 Oct 25;14:1255935. doi: 10.3389/fmicb.2023.1255935. eCollection 2023. Front Microbiol. 2023. PMID: 37954238 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
